Citations (46)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Yongsen Wang, Shuting Tang, Lingling Li, Cheng Sun, Yaru Liu & Yujie Zhao. (2022) Depletion of circPDSS1 inhibits ITGA11 production to confer cisplatin sensitivity through miR-515-5p in gastric cancer. Journal of Chemotherapy 0:0, pages 1-13.
Read now
Read now
Jianjun Wang, Kunxian Yang, Junyu Cao & Li Li. (2021) Knockdown of circular RNA septin 9 inhibits the malignant progression of breast cancer by reducing the expression of solute carrier family 1 member 5 in a microRNA-149-5p-dependent manner. Bioengineered 12:2, pages 10624-10637.
Read now
Read now
Daolin Ji, Wangyang Zheng, Peng Huang, Yue Yao, Xiangyu Zhong, Pengcheng Kang, Zhidong Wang, Guojing Shi, Yi Xu & Yunfu Cui. (2020) Huaier Restrains Cholangiocarcinoma Progression in vitro and in vivo Through Modulating lncRNA TP73-AS1 and Inducing Oxidative Stress. OncoTargets and Therapy 13, pages 7819-7837.
Read now
Read now
Feihu Hu, Chenhai Liu, Fang Xie, Xiansheng Lin, Ji Yang, Chao Wang & Qiang Huang. (2018) MSI2 knockdown represses extrahepatic cholangiocarcinoma growth and invasion by inhibiting epithelial–mesenchymal transition. OncoTargets and Therapy 11, pages 4035-4046.
Read now
Read now
Charupong Saengboonmee, Kanlayanee Sawanyawisuth, Yaovalux Chamgramol & Sopit Wongkham. (2018) Prognostic biomarkers for cholangiocarcinoma and their clinical implications. Expert Review of Anticancer Therapy 18:6, pages 579-592.
Read now
Read now
Articles from other publishers (41)
Guihua Sun, Jing Tian, Yifang Xiao & Youling Zeng. (2023) Circular RNA circ_0005667 promotes cisplatin resistance of endometrial carcinoma cells by regulating IGF2BP1 through miR-145-5p. Anti-Cancer Drugs 34:7, pages 816-826.
Crossref
Crossref
Rui Song, Ting Chai, Junqi Liu, Alan Chu, Chen Sun & Zongwen Liu. (2023) Knockdown of circMFN2 inhibits cell progression and glycolysis by miR‐198/CUL4B pathway in ovarian cancer. Journal of Biochemical and Molecular Toxicology 37:8.
Crossref
Crossref
Mei Zheng, Lingli Xu, Cuifeng Wei & Wenzhen Guan. (2023) CircRTN1 stimulates HMGB1 to regulate the malignant progression of papillary thyroid cancer by sponging miR-101-3p. Hormones 22:2, pages 281-293.
Crossref
Crossref
Lihua Yu, Feifei Zhang & Yeli Wang. (2023) Circ_0005615 Regulates the Progression of Colorectal Cancer Through the miR-873-5p/FOSL2 Signaling Pathway. Biochemical Genetics.
Crossref
Crossref
Lijun Zhao, Junying Fan, Chunyang Zhang, Zhenjun Zhang & Jun Dong. (2023) CircRANBP17 modulated KDM1A to regulate neuroblastoma progression by sponging miR-27b-3p. Open Medicine 18:1.
Crossref
Crossref
Dan Zhang, Jingting Liu, Mengxia Zheng, Chunyan Meng & Jianhua Liao. (2022) Prognostic and clinicopathological significance of CD155 expression in cancer patients: a meta-analysis. World Journal of Surgical Oncology 20:1.
Crossref
Crossref
Hong-Guang Li, Li-Hong Zhao, Jun-Zhao Liu, Kun-Peng Liu, Jian-Bo Liu, Zi-Jie Su & Yong-Ju Gao. (2022) Silencing circ_0000644 inhibits papillary thyroid cancer cell malignancy by combining with miR-671-5p to release the inhibition on ANXA2. Journal of Endocrinological Investigation 46:4, pages 749-761.
Crossref
Crossref
Hong Zhang, Qi Zhou & Jue Jiang. (2022) Circ_0027446 induces CLDN1 expression to promote papillary thyroid cancer cell malignancy by binding to miR-129–5p. Pathology - Research and Practice 238, pages 154095.
Crossref
Crossref
Meixiao Zhan, Zhiren Zhang, Xiaoguang Zhao, Yuncong Zhang, Tianqing Liu, Ligong Lu & Xian-Yang Li. (2022) CD155 in tumor progression and targeted therapy. Cancer Letters 545, pages 215830.
Crossref
Crossref
Yu-Hang Duan, Yan-lin Bian & Jian-Wei Zhu. (2022) Generating Anti-TIGIT and CD155 Monoclonal Antibodies for Tumor Immunotherapy. Pharmaceutical Fronts 04:03, pages e197-e206.
Crossref
Crossref
Shyam Sundar Nandi, Trupti Gohil, Sonali Ankush Sawant, Upendra Pradeep Lambe, Sudip Ghosh & Snehasis Jana. (2022) CD155: A Key Receptor Playing Diversified Roles. Current Molecular Medicine 22:7, pages 594-607.
Crossref
Crossref
Michael Conner, Ken W. Hance, Sapna Yadavilli, James Smothers & Jeremy D. Waight. (2022) Emergence of the CD226 Axis in Cancer Immunotherapy. Frontiers in Immunology 13.
Crossref
Crossref
Hongyang Li, Hailin Yin & Yao Yan. (2022) Circ_0041732 regulates tumor properties of triple-negative breast cancer cells by the miR-149-5p/FGF5 pathway. The International Journal of Biological Markers 37:2, pages 178-190.
Crossref
Crossref
Byung-Hyun Lee, Ji-Hea Kim, Ka-Won Kang, Se-Ryeon Lee, Yong Park, Hwa-Jung Sung & Byung-Soo Kim. (2022) PVR (CD155) Expression as a Potential Prognostic Marker in Multiple Myeloma. Biomedicines 10:5, pages 1099.
Crossref
Crossref
Hana Triki, Ken Declerck, Slim Charfi, Wala Ben Kridis, Kais Chaabane, Sawssan Ben Halima, Tahya Sellami, Ahmed Rebai, Wim Vanden Berghe & Boutheina Cherif. (2021) Immune checkpoint CD155 promoter methylation profiling reveals cancer-associated behaviors within breast neoplasia. Cancer Immunology, Immunotherapy 71:5, pages 1139-1155.
Crossref
Crossref
Xiangrong Tan, Jiazheng Zhao, Jianlin Lou, Wen Zheng & Peng Wang. (2022) Hsa_circ_0058129 regulates papillary thyroid cancer development via miR‐873‐5p/follistatin‐like 1 axis. Journal of Clinical Laboratory Analysis 36:5.
Crossref
Crossref
Juan Chen, Li Xu, Mingzhi Fang, Yahong Xue, Yan Cheng & Xiuhong Tang. (2022) Hsa_circ_0060927 participates in the regulation of Caudatin on colorectal cancer malignant progression by sponging miR‐421/miR‐195‐5p. Journal of Clinical Laboratory Analysis 36:5.
Crossref
Crossref
An‐Li Jin, Chun‐Yan Zhang, Wen‐Jing Zheng, Jing‐Rong Xian, Wen‐Jing Yang, Te Liu, Wei Chen, Tong Li, Bei‐Li Wang, Bai‐Shen Pan, Qian Li, Jian‐Wen Cheng, Peng‐Xiang Wang, Bo Hu, Jian Zhou, Jia Fan, Xin‐Rong Yang & Wei Guo. (2022) CD155/SRC complex promotes hepatocellular carcinoma progression via inhibiting the p38 MAPK signalling pathway and correlates with poor prognosis. Clinical and Translational Medicine 12:4.
Crossref
Crossref
Daisuke Murakami, Kenji Matsuda, Hiromitsu Iwamoto, Yasuyuki Mitani, Yuki Mizumoto, Yuki Nakamura, Ibu Matsuzaki, Ryuta Iwamoto, Yuichi Takahashi, Fumiyoshi Kojima, Shin-ichi Murata & Hiroki Yamaue. (2022) Prognostic value of CD155/TIGIT expression in patients with colorectal cancer. PLOS ONE 17:3, pages e0265908.
Crossref
Crossref
Niharika B. Mettu, Susanna V. Ulahannan, Johanna C. Bendell, Ignacio Garrido-Laguna, John H. Strickler, Kathleen N. Moore, Robert Stagg, Ann M. Kapoun, Leonardo Faoro & Sunil Sharma. (2022) A Phase 1a/b Open-Label, Dose-Escalation Study of Etigilimab Alone or in Combination with Nivolumab in Patients with Locally Advanced or Metastatic Solid Tumors. Clinical Cancer Research 28:5, pages 882-892.
Crossref
Crossref
Sandra Pavicevic, Sophie Reichelt, Deniz Uluk, Isabella Lurje, Cornelius Engelmann, Dominik P. Modest, Uwe Pelzer, Felix Krenzien, Nathanael Raschzok, Christian Benzing, Igor M. Sauer, Sebastian Stintzing, Frank Tacke, Wenzel Schöning, Moritz Schmelzle, Johann Pratschke & Georg Lurje. (2022) Prognostic and Predictive Molecular Markers in Cholangiocarcinoma. Cancers 14:4, pages 1026.
Crossref
Crossref
Jun Wang, Juan Li, Peng Duan, Yanwei Dang & Tao Shi. (2022) Circ_0001588 Upregulates ERBB4 to Promote Glioma Malignant Progression Through Sponging miR-1281. Neurotoxicity Research 40:1, pages 89-102.
Crossref
Crossref
Guoying Zhou, Patrick P. C. Boor, Marco J. Bruno, Dave Sprengers & Jaap Kwekkeboom. (2021) Immune suppressive checkpoint interactions in the tumour microenvironment of primary liver cancers. British Journal of Cancer 126:1, pages 10-23.
Crossref
Crossref
Danzan Mansorunov, Natalya Apanovich, Pavel Apanovich, Fatimat Kipkeeva, Tatyana Muzaffarova, Anna Kuzevanova, Maxim Nikulin, Olga Malikhova & Alexander Karpukhin. (2021) Expression of Immune Checkpoints in Malignant Tumors: Therapy Targets and Biomarkers for the Gastric Cancer Prognosis. Diagnostics 11:12, pages 2370.
Crossref
Crossref
Guojiu Fang, Yibin Wu & Xueli Zhang. (2021) CircASXL1 knockdown represses the progression of colorectal cancer by downregulating GRIK3 expression by sponging miR-1205. World Journal of Surgical Oncology 19:1.
Crossref
Crossref
Hong Zhang, Haojian Zhang, Jiye Zhu, Huan Liu & Qin Zhou. (2021) PESV represses non-small cell lung cancer cell malignancy through circ_0016760 under hypoxia. Cancer Cell International 21:1.
Crossref
Crossref
Jingping Zhou, Shaolong Zhang & Changying Guo. (2021) Crosstalk between macrophages and natural killer cells in the tumor microenvironment. International Immunopharmacology 101, pages 108374.
Crossref
Crossref
Lu Liu, Ying Wang, Chen Geng, Aihong Wang, Sai Han, Xuewu You, Yu Sun, Junhua Zhang, Wei Lu & Youzhong Zhang. (2021) CD155 Promotes the Progression of Cervical Cancer Cells Through AKT/mTOR and NF-κB Pathways. Frontiers in Oncology 11.
Crossref
Crossref
Cong Luo, Wenrui Ye, Jiao Hu, Belaydi Othmane, Huihuang Li, Jinbo Chen & Xiongbing Zu. (2021) A Poliovirus Receptor (CD155)-Related Risk Signature Predicts the Prognosis of Bladder Cancer. Frontiers in Oncology 11.
Crossref
Crossref
Robert J. JohnstonPeter S. LeePavel StropMark J. Smyth. (2021) Cancer Immunotherapy and the Nectin Family. Annual Review of Cancer Biology 5:1, pages 203-219.
Crossref
Crossref
Hongpan Zhang, Zhihao Yang, Guobo Du, Lu Cao & BangXian Tan. (2021) CD155-Prognostic and Immunotherapeutic Implications Based on Multiple Analyses of Databases Across 33 Human Cancers. Technology in Cancer Research & Treatment 20, pages 153303382098008.
Crossref
Crossref
Kyle B. Lupo & Sandro Matosevic. (2020) CD155 immunoregulation as a target for natural killer cell immunotherapy in glioblastoma. Journal of Hematology & Oncology 13:1.
Crossref
Crossref
Jake. S. O’Donnell, Jason Madore, Xian-Yang Li & Mark J. Smyth. (2020) Tumor intrinsic and extrinsic immune functions of CD155. Seminars in Cancer Biology 65, pages 189-196.
Crossref
Crossref
Hui You, Yi-Zhong Zhang, Huan-Ling Lai, Dan Li, Yu-Quan Liu, Run-Ze Li, Imran Khan, Wendy Wen-Lun Hsiao, Fu-Gang Duan, Xing-Xing Fan, Xiao-Jun Yao, Ya-Bing Cao, Qi-Biao Wu, Elaine Lai-Han Leung & Mei-Fang Wang. (2020) Prognostic significance of tumor poliovirus receptor and CTLA4 expression in patients with surgically resected non-small-cell lung cancer. Journal of Cancer Research and Clinical Oncology 146:6, pages 1441-1450.
Crossref
Crossref
Yu Sun, Jiping Luo, Yangshan Chen, Ji Cui, Yiyan Lei, Yongmei Cui, Neng Jiang, Wenting Jiang, Lili Chen, Yanyang Chen, Yukun Kuang, Kejing Tang & Zunfu Ke. (2020) Combined evaluation of the expression status of CD155 and TIGIT plays an important role in the prognosis of LUAD (lung adenocarcinoma). International Immunopharmacology 80, pages 106198.
Crossref
Crossref
Lei Wu, Liang Mao, Jian-Feng Liu, Lei Chen, Guang-Tao Yu, Lei-Lei Yang, Hao Wu, Lin-Lin Bu, Ashok B. Kulkarni, Wen-Feng Zhang & Zhi-Jun Sun. (2019) Blockade of TIGIT/CD155 Signaling Reverses T-cell Exhaustion and Enhances Antitumor Capability in Head and Neck Squamous Cell Carcinoma. Cancer Immunology Research 7:10, pages 1700-1713.
Crossref
Crossref
Juichiro Yoshida, Takeshi Ishikawa, Toshifumi Doi, Takayuki Ota, Tomoyo Yasuda, Tetsuya Okayama, Naoyuki Sakamoto, Ken Inoue, Osamu Dohi, Naohisa Yoshida, Kazuhiro Kamada, Kazuhiko Uchiyama, Tomohisa Takagi, Hideyuki Konishi, Yuji Naito & Yoshito Itoh. (2019) Clinical significance of soluble forms of immune checkpoint molecules in advanced esophageal cancer. Medical Oncology 36:7.
Crossref
Crossref
Roberto Tamma, Tiziana Annese, Simona Ruggieri, Oronzo Brunetti, Vito Longo, Eliano Cascardi, Mauro Giuseppe Mastropasqua, Eugenio Maiorano, Nicola Silvestris & Domenico Ribatti. (2019) Inflammatory cells infiltrate and angiogenesis in locally advanced and metastatic cholangiocarcinoma. European Journal of Clinical Investigation 49:5, pages e13087.
Crossref
Crossref
雨生 张. (2019) The Expression of CD155 on Renal Cell Carcinoma Cells. Advances in Clinical Medicine 09:03, pages 373-381.
Crossref
Crossref
Paola Kučan Brlić, Tihana Lenac Roviš, Guy Cinamon, Pini Tsukerman, Ofer Mandelboim & Stipan Jonjić. (2018) Targeting PVR (CD155) and its receptors in anti-tumor therapy. Cellular & Molecular Immunology 16:1, pages 40-52.
Crossref
Crossref
Xian-Yang Li, Indrajit Das, Ailin Lepletier, Venkateswar Addala, Tobias Bald, Kimberley Stannard, Deborah Barkauskas, Jing Liu, Amelia Roman Aguilera, Kazuyoshi Takeda, Matthias Braun, Kyohei Nakamura, Sebastien Jacquelin, Steven W. Lane, Michele W.L. Teng, William C. Dougall & Mark J. Smyth. (2018) CD155 loss enhances tumor suppression via combined host and tumor-intrinsic mechanisms. Journal of Clinical Investigation 128:6, pages 2613-2625.
Crossref
Crossref